Last reviewed · How we verify
Leukine
At a glance
| Generic name | Leukine |
|---|---|
| Also known as | Sargramostim, GM-CSF, GM-CSF [Leukine (Sargramostim)] |
| Sponsor | University of Kentucky |
| Target | Granulocyte macrophage colony-stimulating factor receptor |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | discontinued |
Approved indications
- Chemotherapy-induced neutropenia
Common side effects
Key clinical trials
- INTRALESIONAL IMMUNOTHERAPY WITH A VACCINIA/GM-CSF RECOMBINANT VIRUS IN PATIENTS WITH METASTATIC MELANOMA (Phase 1)
- Pilot Study of Umbilical Cord Blood Transplantation in Adult Patients With Advanced Hematopoietic Malignancies (Phase 1)
- A Multicenter, Randomized, Placebo-Controlled, Double-Blinded, Phase I Trial to Evaluate the Safety and Immunogenicity of Live Recombinant Canarypox ALVAC-HIV vCP205, Combined With Granulocyte-Macroph (Phase 1)
- Randomized Study of Vincristine, Actinomycin-D, and Cyclophosphamide (VAC) Versus VAC Alternating With Vincristine, Topotecan and Cyclophosphamide for Patients With Intermediate Risk Rhabdomyosarcoma (Phase 3)
- Endogenous Heat-shock Vaccines for Melanoma A Feasibility Study (Phase 1)
- Safety of UV1 Vaccination in Combination With Ipilimumab in Patients With Unresectable or Metastatic Malignant Melanoma (Phase 1)
- A Randomized Phase II Continuation Booster Trial After A Vaccine Combining Tyrosinase/GP100/Mart-1 Peptides Emulsified With Montanide ISA 51 and ISA 51 VG With Or Without GM-CSF For Patients With Rese (Phase 2)
- Randomized, Open-Label Study of the Bria-IMT Regimen and Check Point Inhibitor vs Physicians' Choice in Advanced Metastatic Breast Cancer. (Phase 3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Leukine CI brief — competitive landscape report
- Leukine updates RSS · CI watch RSS
- University of Kentucky portfolio CI